tradingkey.logo

Moderna Inc

MRNA
View Detailed Chart
41.010USD
+0.140+0.34%
Close 02/06, 16:00ETQuotes delayed by 15 min
16.03BMarket Cap
LossP/E TTM

Moderna Inc

41.010
+0.140+0.34%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.34%

5 Days

-6.94%

1 Month

+15.00%

6 Months

+53.54%

Year to Date

+39.06%

1 Year

+22.02%

View Detailed Chart

TradingKey Stock Score of Moderna Inc

Currency: USD Updated: 2026-02-06

Key Insights

Moderna Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 70 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 38.91.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Moderna Inc's Score

Industry at a Glance

Industry Ranking
70 / 159
Overall Ranking
185 / 4521
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

1°C

Very Low
Very High
Neutral

Moderna Inc Highlights

StrengthsRisks
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Fairly Valued
The company’s latest PE is -5.10, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 297.63M shares, decreasing 5.63% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 38.77K shares of this stock.

Analyst Rating

Based on 25 analysts
Hold
Current Rating
38.906
Target Price
-4.81%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Moderna Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Moderna Inc Info

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Ticker SymbolMRNA
CompanyModerna Inc
CEOBancel (Stephane)
Websitehttps://www.modernatx.com/
KeyAI